MedPath

Expanded Access Protocol Using HBOC-201

Conditions
Anemia
Registration Number
NCT02684474
Lead Sponsor
Johns Hopkins University
Brief Summary

The purpose of this protocol is to provide treatment with HBOC-201 to patients with life-threatening anemia for whom allogeneic blood transfusion is not an option. HBOC 201 \[hemoglobin glutamer - 250 (bovine)\] has been previously studied as an alternative to blood transfusions in severely anemic patients needing a way to enhance tissue oxygenation. HBOC-201 is purified, cross-linked and polymerized acellular bovine hemoglobin in a modified lactated Ringer's solution, and does not require blood compatibility.

Detailed Description

Not available

Recruitment & Eligibility

Status
AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Patients ≥ 18 years of age

  2. Critically ill patients with hemoglobin ≤ 6 g/dL (or 7-8 g/dL with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits

  3. Patients or their Legally Authorized Representative who are able and willing to provide informed consent

  4. Blood is not an option due to:

    • refusal of transfusion
    • lack of compatible red blood cells
Exclusion Criteria
  1. Patients with known hypersensitivity or allergy to beef products

  2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis*

  3. Patients who are eligible for blood transfusions

  4. Patients who are > 80 years old*

    • on a case by case and quality of life determination

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The Johns Hopkins Hospital

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath